Uses of human monoclonal antibodies against oxidized LDL receptor
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 9, 2011
Grant Date -
Oct 2, 2008
app pub date -
Apr 26, 2007
filing date -
Mar 2, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully